Evidence map›Paper›PMID 24430948›Full record

ArticleMolecular diagnosis & therapy2014

Lack of association of the p450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients.

Georgia Ragia, Vana Kolovou, Anna Tavridou, Laure Elens, Alexandros D Tselepis, Moses Elisaf, Ron H N Van Schaik, Genovefa Kolovou, Vangelis G Manolopoulos

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diagnosis & therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
4.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 3 countries.

Georgia RagiaLaboratory of Pharmacology, Medical School, Democritus University of Thrace, Dragana Campus, 68100, Alexandroupolis, Greece.
Vana Kolovou
Anna Tavridou
Laure Elens
Alexandros D Tselepis
Moses Elisaf
Ron H N Van Schaik
Genovefa Kolovou
Vangelis G Manolopoulos
Democritus University of Thrace · GROnassis Cardiac Surgery Center · GRUniversity of Ioannina · GRErasmus MC · NLErasmus University Rotterdam · NLUniversity Hospital of Alexandroupolis · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveInter-individual variability exists in the statin (HMG-CoA reductase inhibitor) lipid-lowering response, which is partially attributed to genetic factors. The polymorphic enzyme P450 oxidoreductase (POR) transfers electrons from nicotinamide adenine dinucleotide phosphate (NADPH) to cytochrome P450 (CYP) 3A enzymes, which metabolize atorvastatin and simvastatin. The POR*28 allele is associated with increased activity of CYP3A enzymes. We analyzed the association of the POR*28 allele with response to atorvastatin and simvastatin.

methodsA total of 207 atorvastatin-treated adults were included in the study. An independent population of 210 simvastatin-treated adults served as a replication cohort. Total cholesterol (TChol) and low-density lipoprotein cholesterol (LDL-C) were measured at baseline and after 6 months of treatment. The POR*28 allele was analyzed with a TaqMan(®) assay.

resultsThe POR*28 allele was associated with a non-significant trend towards lower percentage mean reduction of TChol (-35.5 % in *1/*1, -33.7 % in *1/*28, and -29.5 % in *28/*28 individuals) and LDL-C (-42.6 % in *1/*1, -41.7 % in *1/*28, and -37.8 % in *28/*28 individuals) in response to atorvastatin. This trend was not observed in the replication cohort of simvastatin-treated patients. No sex-gene interaction was observed regarding the effect of the POR*28 allele on the statin lipid-lowering response in either statin-treated patient cohort.

conclusionThe POR*28 allele was not associated with the lipid-lowering effect of atorvastatin and the results were replicated in an independent simvastatin-treated population. The hypothesized effect of the POR*28 allele on the lipid-lowering response to CYP3A-metabolized statins can potentially be masked by relevant confounding or uncontrolled factors; therefore, further studies in different populations are required.

Indexed as

AdultAgedAtorvastatinCholesterolCohort StudiesCytochrome P-450 CYP3AFemaleGene FrequencyGenetic Association StudiesGenotypeHeptanoic AcidsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaMaleMiddle AgedAtorvastatinCholesterolCYP3A4 protein, humanCytochrome P-450 CYP3AHeptanoic AcidsHydroxymethylglutaryl-CoA Reductase InhibitorsNADPH-Ferrihemoprotein ReductasePyrrolesSimvastatin

Identifiers

PMID24430948
OpenAlexW2078215542

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.